Showing results (51-60 of 91) with videos related to
Sort By:
Pageof 10
Hematological Oncology|October 1, 1984
The management of localized, infradiaphragmatic Hodgkin's disease: experience of a rare clinical presentation at St Bartholomew's HospitalM S Dorreen, P F Wrigley, A E Jones, et al.Human & Experimental Toxicology|July 1, 1992
Indomethacin and protein binding of methotrexateR Raveendran, W Heybroek, M Caulfield, et al.Hematological Oncology|April 1, 1987
OPEC chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's diseaseM J Barnett, A M Man, M A Richards, et al.British Journal of Cancer|April 1, 1988
Low field strength magnetic resonance imaging of the spleen: results from volunteers and patients with lymphomaM A Richards, J A Webb, S E Jewell, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1979
Cyclic nucleotide phosphodiesterase activity in human peripheral blood lymphocytes and monocytesH J Wedner, B Y Chan, C S Parker, et al.Proceedings of the National Academy of Sciences of the United States of America|August 1, 1992
dOct2, a Drosophila Oct transcription factor that functions in yeastK Prakash, X D Fang, D Engelberg, et al.Cancer Chemotherapy and Pharmacology|January 1, 1984
The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycleV J Harvey, M L Slevin, R C Woollard, et al.Cancer Chemotherapy and Pharmacology|January 1, 1989
The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observationM L Slevin, S P Joel, R Whomsley, et al.Cancer Chemotherapy and Pharmacology|January 1, 1986
EVA treatment for recurrent or unresponsive Hodgkin's diseaseM A Richards, J H Waxman, T Man, et al.Cancer Chemotherapy and Pharmacology|January 1, 1985
The treatment of postmenopausal women with advanced breast cancer with buserelinJ H Waxman, S J Harland, R C Coombes, et al.Pageof 10